Late-stage venture AI companies in New York

Sequencing is building the lifelong home for every genome on Earth and the foundational platform for the AI-native genomic era.The human genome is the world’s most valuable untapped resource and one of the defining datasets of the 21st century. Every person with DNA will need a trusted platform to store, interpret, and continuously benefit from their genomic data throughout their lifetime. Sequencing is building that platform.As the world’s largest provider of clinical-grade whole genome sequencing (WGS) services, Sequencing has sequenced more whole genomes than any other company - creating the largest foundation for genomic intelligence and personalized health.We combine whole genome sequencing, AI-powered interpretation, and a rapidly expanding ecosystem of genomic applications and integrations to transform DNA from a static file into a dynamic, continuously evolving source of actionable intelligence.Our platform enables individuals, families, healthcare professionals, and other healthtech companies to unlock insights spanning disease prevention, inherited conditions, medication response, reproductive planning, wellness optimization, and longevity - turning the genome into each person's most valuable lifelong health asset.We envision a future where genomic intelligence is deeply integrated into everyday life for billions of people, powering a new era of personalization, precision medicine, preventative healthcare, and human optimization.We are a fully remote global company of doctors, scientists, engineers, AI researchers, and builders committed to making genomics accessible, actionable, and transformative for humanity.

• Series unknown
• 43 employees
• Founded 2017

MEDICI is the #1 destination for the global FinTech industry. The proprietary media and insights platform covering 15,000+ companies across 60+ FinTech sub-segments now supports the largest community in FinTech with an audience of 200,000+ executive leaders, innovators and investors. MEDICI's Inner Circle membership for individuals caters to the rapidly growing interest in the space with a daily curated feed, personalised bi-weekly newsletter, monthly deep dives and preferred access to exclusive events. https://gomedici.com/insightsThe MEDICI Advisory membership allows enterprises (banks, financial institutions, insurance companies, pre-IPO startups and corporates in other industries) to engage with the early stage FinTech ecosystem and build new experiences via collaborative innovation. https://gomedici.comMEDICI Studio helps companies of all sizes to stand out and showcase their innovations via thought leadership content fueled by the MEDICI platform's deep domain depth and research-driven context. https://studio.gomedici.com

• Series unknown
• 40 employees
• Founded 2013

Overview:AccutarBio employs artificial intelligence to revolutionize drug discovery. With capabilities in side chain flexible mode ligand docking, virtual screening, and drug ADME property prediction, Accutar’s platform beats the industry standard in computation-aided drug design. The company’s hybrid based approach, which uses computational drug design followed by wet lab validation, greatly reduces the time and cost necessary for traditional drug discovery efforts. Accutar is committed to building strong partnerships, and collaborates across academia and the pharmaceutical industry to solve interdisciplinary problems. The company was founded in 2015 and has locations in both Shanghai, China and New York, NY.Products & Services:Accutar offers two software packages: Chemi-Net and Orbital. Chemi-Net is a molecular graph convolutional network for accurate drug property prediction. It was recently shown to improve the accuracy of ADME property prediction by a large margin in comparison to the widely-used methods https://arxiv.org/abs/1803.06236. Orbital is a deep neural network based docking platform. The prediction accuracy of protein-ligand complex (holo) from ligand free state (apo) structure is significantly higher than current standards. In addition to these tools, AccutarBio offers services in virtual screening for lead discovery; intelligent-SAR for lead optimization and drug property prediction.

• Series unknown
• 39 employees
• Founded 2015

L2 is a member-based business intelligence firm that benchmarks the digital performance of brands. We publish research across 12 sectors, host executive education events globally, and deliver data-driven insights to brands seeking greater return on their digital investments. The firm was founded in 2010, has over 150 employees and offices in NYC and London. Learn more at www.L2Inc.com.

• Series unknown
• 36 employees
• Founded 2010

ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.

• Series unknown
• 33 employees
• Founded 2016